Welcome to our dedicated page for Mindset Pharma news (Ticker: MSSTF), a resource for investors and traders seeking the latest updates and insights on Mindset Pharma stock.
Mindset Pharma Inc. is a drug discovery company that focuses on developing novel psychedelic and non-psychedelic medications to address neuropsychiatric and neurological disorders with unmet medical needs. The company recently entered into a definitive arrangement agreement with Otsuka Pharmaceutical Co., Ltd., signaling a significant acquisition worth approximately CAD $80 million. Mindset's innovative compounds and synthesis processes aim to revolutionize the treatment of psychiatric disorders, contributing to patient care on a global scale.
The Transaction, expected to close in October 2023, marks a strategic move by Otsuka to strengthen its presence in the psychiatry and neurology therapeutic areas. Mindset's shareholders will benefit from the all-cash acquisition, demonstrating a premium value of $0.75 per share. With a focus on maximizing the value of its assets and IP portfolio, Mindset's collaboration with Otsuka is poised to lead to groundbreaking advancements in patient treatment.
In pursuit of its mission to develop next-generation pharmaceutical assets, Mindset is dedicated to creating optimized and patentable psychedelic medicines, leveraging the therapeutic potential of psychedelic drugs. Through proprietary compounds, novel families of psychedelic compounds, and innovative synthesis processes, the company is at the forefront of advancing treatment options for neurological and psychiatric conditions.
Mindset Pharma (OTCQB: MSSTF) has identified Treatment-Resistant Depression (TRD) and End of Life Angst as target indications for its lead candidate, MSP-1014. This drug aims to provide a safer second-generation treatment over psilocybin, which has shown efficacy in addressing these conditions. According to CEO James Lanthier, TRD affects one-third of major depressive disorder patients, representing a significant unmet need. Preclinical data shows MSP-1014 may offer improved safety and scalability compared to psilocybin, aiding in efficient manufacturing.
Mindset Pharma (OTCQB:MSSTF) announced groundbreaking advances in confirming the psychedelic effects of its novel compounds. Collaborating with InterVivo Solutions, the company has trained rats to distinguish psilocybin from saline, enhancing efficacy and safety assessments for its psychedelic drug candidates. This research noted that LSD demonstrated greater potency compared to psilocybin. CEO James Lanthier emphasized this innovative approach strengthens the potential of Mindset's compounds as they progress to clinical trials.
Mindset Pharma Inc. (OTCQB: MSSTF) announced CEO James Lanthier's participation in three upcoming virtual investor conferences. The conferences are the H.C. Wainwright 23rd Annual Global Investment Conference (Sept 13-15), Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Sept 20-23), and Maxim's Advances in Mental Health Conference (Sept 22). These events aim to showcase the company’s significant advancements in developing next-generation psychedelic therapies targeting neurological and psychiatric disorders. For more information, visit mindsetpharma.com.
Mindset Pharma Inc. (OTCQB: MSSTF) recently announced promising results from its next-generation 5-MeO-DMT drug candidates, showing a significant decrease in serotonergic toxicity. These findings reaffirm the candidates' superior efficacy and safety compared to traditional 5-MeO-DMT. According to CEO James Lanthier, the results highlight the potential for these drug candidates to provide a safer solution for clinic-based therapeutic use, potentially mitigating the health risks associated with serotonergic toxicity.
On August 26, 2021, Mindset Pharma (OTCQB: MSSTF) announced promising preclinical results for its Family 3 compounds, which are long-acting psilocybin analogs. These compounds demonstrated a significantly reduced effect size on the 5-HT2A receptor, suggesting enhanced safety and efficacy for microdosing therapies. The findings indicate potential for effective low-dose administration without the hallucinogenic effects typical of psilocybin. The company plans further testing in preclinical models to explore cognitive benefits.
Mindset Pharma Inc. (OTCQB: MSSTF) has filed a new provisional patent application with the USPTO for its Family 4 compounds, which are novel DMT/5-MeO-DMT analogs. This new application expands the range of drug candidates and their synthesis processes. CEO James Lanthier highlighted the pharmacological diversity of these compounds, which may provide more personalized therapies in clinical settings. The company is moving closer to human clinical trials after successful preliminary in-vitro and in-vivo tests.
Mindset Pharma Inc. (OTCQB: MSSTF) has announced the publication of three PCT patent applications covering novel compounds designed to enhance the therapeutic effects of psilocybin. These applications include a range of proprietary compounds with lower safety liabilities and improved efficacy. CEO James Lanthier emphasized the first-to-file advantage and ongoing testing to validate these compounds. The Family 1 compounds aim to improve pharmacokinetics, while Family 2 compounds are set for clinical trials. This development underscores Mindset's commitment to advancing psychedelic medicine.
Mindset Pharma Inc. (OTCQB: MSSTF) has reported promising results from its next-generation psychedelic compounds, which include psilocybin/psilocin and DMT/5-MeO-DMT analogs. These compounds displayed enhanced efficacy, safety, and shorter durations compared to traditional drugs in preclinical tests. Initial studies indicate that Family 2 compounds show up to 10 times the efficacy of psilocin, while Family 4 compounds exhibit diverse pharmacological effects. Mindset aims to optimize these compounds for clinical settings, progressing towards human trials.
Mindset Pharma (OTCQB:MSSTF) announced the filing of an international patent application for its innovative psilocybin synthesis method, claiming priority from a prior U.S. filing dated July 24, 2020. This synthesis process promises advantages including lower cost, milder reaction conditions, and suitability for large-scale manufacturing. The company is collaborating with a leading CDMO for optimization and plans to initiate pilot-scale synthesis by 2021's end. Mindset's CEO highlighted the potential for significant demand in cGMP psilocybin for ongoing trials, showcasing a strong revenue opportunity.
Mindset Pharma Inc. (OTCQB: MSSTF) has appointed Dr. Ishrat Husain to its Scientific Advisory Board to guide the development of regulatory pathways for its novel psychedelic therapies. Dr. Husain, an expert in mood disorders, is currently engaged in clinical trials and has published over 40 research papers. His extensive experience in clinical trials and psychiatry will aid Mindset as it progresses toward FDA approval, aiming to provide effective treatments for mental illness. This milestone reflects Mindset's commitment to advancing psychedelic-inspired therapeutic solutions.
FAQ
What is the market cap of Mindset Pharma (MSSTF)?
What is Mindset Pharma Inc. focused on?
What recent agreement did Mindset Pharma Inc. enter into?
How will the acquisition benefit Mindset Pharma Inc.'s shareholders?
What is the focus of Mindset Pharma Inc.'s drug development programs?
What is the expected timeline for the completion of the Transaction between Mindset Pharma Inc. and Otsuka Pharmaceutical Co., Ltd.?
How does the collaboration between Mindset Pharma Inc. and Otsuka Pharmaceutical Co., Ltd. contribute to patient care?
What sets Mindset Pharma Inc. apart in the pharmaceutical industry?
